|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...1920212223242526272829...4041» |
- Trial completion, Adverse events: Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis (clinicaltrials.gov) - Apr 23, 2014
P1/2, N=22, Completed, Sponsor: Royan Institute
Recruiting --> Completed
- Trial initiation date: Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS (clinicaltrials.gov) - Apr 23, 2014
P1, N=10, Recruiting, Sponsor: Royan Institute
Recruiting --> Completed Initiation date: Aug 2012 --> Aug 2013
- || Biomarker, Enrollment change: A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery (clinicaltrials.gov) - Apr 22, 2014
P=N/A, N=600, Recruiting, Sponsor: Sanguine Biosciences
Initiation date: Aug 2012 --> Aug 2013 N=300 --> 600
- ||| Betaseron (IFN-β-1b) / Bayer
Adherence: BETAEVAL: BAY86-5046 (Betaseron), Non Interventional Studies (clinicaltrials.gov) - Apr 21, 2014
P=N/A, N=150, Not yet recruiting, Sponsor: Bayer
- Trial initiation date: Neuropsychiatric Scleroderma Study: Systematic Evaluation of Neuropsychiatric Involvement in Systemic Sclerosis (clinicaltrials.gov) - Apr 21, 2014
P=N/A, N=108, Recruiting, Sponsor: University Hospital, Lille
N=300 --> 600 Initiation date: Dec 2010 --> Feb 2011
- | Tysabri (natalizumab) / Biogen, Royalty
Trial termination: TOFIINGO: Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod (clinicaltrials.gov) - Apr 21, 2014
P3, N=142, Terminated, Sponsor: Novartis Pharmaceuticals
Initiation date: Dec 2010 --> Feb 2011 Completed --> Terminated; Based on recent publications, determination of natalizumub washout period was no longer relevant.
- | Trial completion: ALS Registry: National Registry of Veterans With Amyotrophic Lateral Sclerosis and DNA Bank (clinicaltrials.gov) - Apr 20, 2014
P=N/A, N=2121, Completed, Sponsor: Department of Veterans Affairs
Completed --> Terminated; Based on recent publications, determination of natalizumub washout period was no longer relevant. Active, not recruiting --> Completed
- Clinical: Allocentric Memory in MS and Resting State Functional MRI (clinicaltrials.gov) - Apr 17, 2014
P=N/A, N=120, Recruiting, Sponsor: Yale University
- Trial initiation date: High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases (clinicaltrials.gov) - Apr 17, 2014
P=N/A, N=15, Recruiting, Sponsor: Stanford University
Active, not recruiting --> Completed Initiation date: Oct 2013 --> Apr 2014
- Enrollment change: High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases (clinicaltrials.gov) - Apr 17, 2014
P=N/A, N=15, Recruiting, Sponsor: Stanford University
Initiation date: Oct 2013 --> Apr 2014 N=20 --> 15
- Enrollment open: High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases (clinicaltrials.gov) - Apr 17, 2014
P=N/A, N=15, Recruiting, Sponsor: Stanford University
N=20 --> 15 Not yet recruiting --> Recruiting
- ||||| Rebif (human IFN-β-1a) / EMD Serono
New P4 trial: RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate (clinicaltrials.gov) - Apr 15, 2014
P4, N=90, Not yet recruiting, Sponsor: EMD Serono
- New P1/2 trial: Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Apr 15, 2014
P1/2, N=5, Not yet recruiting, Sponsor: Alzahra Hospital, Iran
- Trial initiation date: A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma (clinicaltrials.gov) - Apr 15, 2014
P=N/A, N=29, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Initiation date: Mar 2013 --> Apr 2013
- | Trial completion: A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma (clinicaltrials.gov) - Apr 15, 2014
P=N/A, N=29, Completed, Sponsor: Gilead Sciences
Initiation date: Mar 2013 --> Apr 2013 Recruiting --> Completed
- || Enrollment change: PRISM Registry: Pseudobulbar Affect Registry Series (clinicaltrials.gov) - Apr 14, 2014
P=N/A, N=5290, Completed, Sponsor: Avanir Pharmaceuticals
Recruiting --> Completed N=10000 --> 5290
- ||| Trial completion: PRISM Registry: Pseudobulbar Affect Registry Series (clinicaltrials.gov) - Apr 14, 2014
P=N/A, N=5290, Completed, Sponsor: Avanir Pharmaceuticals
N=10000 --> 5290 Recruiting --> Completed
- Trial initiation date, Immunomodulating: IMODALS: Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2 (clinicaltrials.gov) - Apr 10, 2014
P1/2, N=24, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
Recruiting --> Completed Initiation date: Apr 2014 --> Oct 2014
- Betaseron (IFN-?-1b) / Bayer
Enrollment closed: Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis (clinicaltrials.gov) - Apr 9, 2014
P=N/A, N=50, Active, not recruiting, Sponsor: Bayer
Initiation date: Apr 2014 --> Oct 2014 Recruiting --> Active, not recruiting
- Enrollment change: Task-oriented Circuit Class Training in Multiple Sclerosis Subjects (clinicaltrials.gov) - Apr 8, 2014
P=N/A, N=24, Completed, Sponsor: University Hospital of Ferrara
Recruiting --> Active, not recruiting N=60 --> 24
- Trial completion: Task-oriented Circuit Class Training in Multiple Sclerosis Subjects (clinicaltrials.gov) - Apr 8, 2014
P=N/A, N=24, Completed, Sponsor: University Hospital of Ferrara
N=60 --> 24 Active, not recruiting --> Completed
- Avonex (recombinant IFN-β-1a) / Biogen
Enrollment change: Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients (clinicaltrials.gov) - Apr 6, 2014
P3, N=3, Terminated, Sponsor: Biogen Idec
Active, not recruiting --> Completed N=150 --> 3
- dalfampridine / Generic mfg.
Enrollment change: Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients (clinicaltrials.gov) - Apr 6, 2014
P=N/A, N=52, Active, not recruiting, Sponsor: Mount Sinai Rehabilitation Hospital
N=150 --> 3 N=120 --> 52
- Enrollment change: Lokomat Treadmill Training Effects on MS Gait (clinicaltrials.gov) - Apr 6, 2014
P=N/A, N=8, Completed, Sponsor: Mount Sinai Rehabilitation Hospital
N=120 --> 52 N=15 --> 8
- dalfampridine / Generic mfg.
Enrollment closed: Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients (clinicaltrials.gov) - Apr 6, 2014
P=N/A, N=52, Active, not recruiting, Sponsor: Mount Sinai Rehabilitation Hospital
N=15 --> 8 Recruiting --> Active, not recruiting
- Trial completion: Effects of Targeted Lower Extremity Joint Training on Multiple Sclerosis (MS) Gait Abnormalities (clinicaltrials.gov) - Apr 6, 2014
P=N/A, N=18, Completed, Sponsor: Mount Sinai Rehabilitation Hospital
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: Lokomat Treadmill Training Effects on MS Gait (clinicaltrials.gov) - Apr 6, 2014
P=N/A, N=8, Completed, Sponsor: Mount Sinai Rehabilitation Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Plegridy (PEG-interferon β-1a) / Biogen
Trial completion: ADVANCE: Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Apr 3, 2014
P3, N=1516, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | oxcarbazepine / Generic mfg.
New P2 trial: PROXIMUS: Protective Role of Oxcarbazepine in Multiple Sclerosis (clinicaltrials.gov) - Apr 2, 2014
P2, N=60, Not yet recruiting, Sponsor: Queen Mary University of London
- propranolol / Generic mfg.
New P2 trial: STBETA: Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers (clinicaltrials.gov) - Apr 2, 2014
P2, N=15, Not yet recruiting, Sponsor: University Hospital, Bordeaux
- | Circadin (melatonin prolonged release) / Lundbeck, Neurim, Flynn Pharma, Grupo Insud, Biocodex, Kuhnil Pharma
Trial completion: Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances (clinicaltrials.gov) - Apr 2, 2014
P1, N=16, Completed, Sponsor: Neurim Pharmaceuticals Ltd.
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment open: SWAMECO: Swallowing Difficulties With Medication Intake and Coping Strategies in Patients With Systemic Sclerosis (clinicaltrials.gov) - Apr 1, 2014
P=N/A, N=50, Recruiting, Sponsor: Kurt Hersberger
Recruiting --> Completed Not yet recruiting --> Recruiting
- Clinical: Implementing Physical Activity Guidelines for Adults With MS (clinicaltrials.gov) - Mar 27, 2014
P=N/A, N=130, Not yet recruiting, Sponsor: McMaster University
- ||||| Sativex (nabiximols) / Jazz
P3 data, Trial initiation date: Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis. (clinicaltrials.gov) - Mar 26, 2014
P3, N=711, Not yet recruiting, Sponsor: GW Pharmaceuticals Ltd.
Not yet recruiting --> Recruiting Initiation date: May 2014 --> Sep 2014
- ||||| Sativex (nabiximols) / Jazz
P3 data, Enrollment change: Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis. (clinicaltrials.gov) - Mar 26, 2014
P3, N=711, Not yet recruiting, Sponsor: GW Pharmaceuticals Ltd.
Initiation date: May 2014 --> Sep 2014 N=300 --> 711
- |||||||||| dimethyl fumarate / Generic mfg.
New P3 trial: Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. (clinicaltrials.gov) - Mar 25, 2014
P3, N=68, Not yet recruiting, Sponsor: Biogen Idec
- Enrollment open: Impact of CRISP on Self-Efficacy, Loneliness, and Depression (clinicaltrials.gov) - Mar 25, 2014
P=N/A, N=100, Recruiting, Sponsor: New York University School of Medicine
N=300 --> 711 Not yet recruiting --> Recruiting
- | New P2 trial: EMR200109_635: Vitamin D3 and the Stress-axis in MS (clinicaltrials.gov) - Mar 24, 2014
P2, N=80, Not yet recruiting, Sponsor: Academic MS Center Limburg
- Biomarker, Enrollment change: BIO_ALS-01: Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 23, 2014
P=N/A, N=475, Active, not recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting N=650 --> 475
- Trial completion: Core Stability Training in Multiple Sclerosis (clinicaltrials.gov) - Mar 20, 2014
P=N/A, N=100, Completed, Sponsor: University of Plymouth
N=650 --> 475 Recruiting --> Completed
- Trial initiation date, Stroma: Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis (clinicaltrials.gov) - Mar 18, 2014
P1/2, N=10, Not yet recruiting, Sponsor: Ageless Regenerative Institute
Recruiting --> Completed Initiation date: May 2011 --> Oct 2014
- Enrollment closed: Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 18, 2014
P2/3, N=14, Active, not recruiting, Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
Initiation date: May 2011 --> Oct 2014 Recruiting --> Active, not recruiting
- || Betaseron (IFN-β-1b) / Bayer
Enrollment closed, Adherence: Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH) (clinicaltrials.gov) - Mar 17, 2014
P=N/A, N=735, Active, not recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| dimethyl fumarate / Generic mfg., aspirin / Generic mfg.
New P4 trial, P4 data: Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Mar 16, 2014
P4, N=240, Not yet recruiting, Sponsor: Biogen Idec
- ||||| dimethyl fumarate / Generic mfg.
New P4 trial: TECNERGY: Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate (clinicaltrials.gov) - Mar 16, 2014
P4, N=320, Not yet recruiting, Sponsor: Biogen Idec
- |||| diazoxide (ATH-012) / Neurotec Pharma, Advancell
Trial completion: A Phase IIa Study of NT-KO-003 for Multiple Sclerosis (clinicaltrials.gov) - Mar 14, 2014
P2a, N=99, Completed, Sponsor: Neurotec Pharma
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial initiation date: Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis (clinicaltrials.gov) - Mar 13, 2014
P1, N=20, Recruiting, Sponsor: Tisch Multiple Sclerosis Research Center of New York
Active, not recruiting --> Completed Initiation date: Oct 2013 --> Mar 2014
- Enrollment open: Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis (clinicaltrials.gov) - Mar 13, 2014
P1, N=20, Recruiting, Sponsor: Tisch Multiple Sclerosis Research Center of New York
Initiation date: Oct 2013 --> Mar 2014 Not yet recruiting --> Recruiting
- Aralast NP (alpha 1-antitrypsin) / Omni Bio Pharma, Takeda
Clinical: A1AT for NMO: Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses (clinicaltrials.gov) - Mar 12, 2014
P1, N=5, Recruiting, Sponsor: Stanford University
- | Enrollment closed: Expiratory Muscle Training for Persons With Neurodegenerative Disease (clinicaltrials.gov) - Mar 12, 2014
P2/3, N=90, Active, not recruiting, Sponsor: Department of Veterans Affairs
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting